Status
Conditions
Treatments
About
The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate hyperlipidemia after 30 days of intervention.
Full description
In a randomized, double-blind, placebo control trial, the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) will be investigated in chronic smokers having mild to moderate hyperlipidemia. Sixty subjects will be randomly assigned to receive the dietary supplements and placebo for 30 days. The efficacy of the supplements will be measured by estimating cotinine and malondialdehyde level.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Men > 20 years
Chronic cigarette/ beedi smoker (2-3 packets/day since last 3 years or more) with mild to moderate hyperlipidemia (LDL ranging 160-189 mg/dL, TC >200 mg/dL and/or HDL-C <40 mg/dL)
Being mentally competent and able to understand all study requirements and sign the informed consent form.
Exclusion criteria
Patients with Chronic obstructive pulmonary disease (COPD)
Women
Patients with severe liver, renal, cardiac or brain diseases.
Unable to complete follow up.
Subjects on any medication like diuretics.
Allergic to any medication.
With a history of alcohol and/or drug abuse.
Primary purpose
Allocation
Interventional model
Masking
60 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Bhanumathy M, M Pharma; Shivaprasad H N, M Pharma, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal